Design and pharmacological characterization of selective P2-purinoceptor antagonists
G. Lambrecht,U. Ardanuy,H.G. Bäumert,X. Bo,C.H.V. Hoyle,P. Nickel,O. Pfaff,V. Ralevic,U. Windscheif,A.U. Ziganshin,R. Ziyal,E. Mutschler,G. Burnstock
DOI: https://doi.org/10.1016/s0165-7208(96)80027-4
1996-01-01
Abstract:At least five distinct P 2 -purinoceptor subtypes have been characterized to date, based on the rank order of potency of several ATP analogues: P 2X , P 2Y , P 2U , P 2T and P 2Z . However, the characterization of P 2 -purinoceptor subtypes is hampered by an unavailability of potent, highly selective, competitive antagonists. In the search for selective P 2 -purinoceptor antagonists, the structure-activity relationships for a series of analogues of pyridoxal-5-phosphate and suramin at P 2 -purinoceptor subtypes were investigated in our laboratories. Two of these compounds were the subject of a more detailed pharmacological characterization: pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid (PPADS) and the symmetrical 3′-urea of 8-(benzamido)naphthalene-1,3,5-trisulfonic acid (NF023). The results demonstrate that the two parent compounds, pyridoxal-5-phosphate and suramin, do not differentiate between P 2X - and P 2Y -purinoceptors. In contrast, PPADS and NF023 were found to be selective antagonists of P 2X -purinoceptor-mediated responses in several smooth muscle preparations. In addition, PPADS and NF023 were shown to displace competitively the binding of [ 3 H]α,β-methylene ATP to rabbit and rat bladder membranes, respectively, which indicates that these two compounds act directly on P 2X -receptors. PPADS and NF023 were ineffective at P 2U -purinoceptors in rat mesenteric arterial bed. P 2T -purinoceptor-mediated platelet aggregation was only affected by PPADS in concentrations higher than 100 μM. Suramin and NF023 were inhibitors of ecto-ATPase activity in the same concentration range needed for P 2 -purinoceptor antagonism. In contrast, PPADS was only very weakly active in inhibiting ecto-ATPase activity. AT 100 μM, PPADS and NF023 did not interact with α 1 -adrenoceptors, adenosine A 1 - and A 2 -, histamine H 1 - and muscarinic M 1 -, M 2 - and M 3 -receptors. In conclusion, PPADS and NF023 are specific P 2 -purinoceptor antagonists showing a high selectivity for the P 2X -subtype. These two compounds may prove to be useful starting points in the synthesis of novel, highly potent and selective antagonists at P 2 -purinoceptor subtypes.